Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS …
CJ Kim, MW Park, MC Kim, EH Choo, BH Hwang… - The Lancet, 2021 - thelancet.com
Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
Coronavirus disease 2019–associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management
L Ortega‐Paz, D Capodanno… - Journal of the …, 2021 - Am Heart Assoc
Abstract Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome coronavirus‐2, which has posed a significant threat to global …
acute respiratory syndrome coronavirus‐2, which has posed a significant threat to global …
[HTML][HTML] Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
P Paolisso, L Bergamaschi, F Gragnano… - Pharmacological …, 2023 - Elsevier
Aims To investigate in-hospital and long-term prognosis in T2DM patients presenting with
acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents …
acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents …
Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19
1 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right …
This position paper provides a comprehensive guide for optimal follow-up of patients with
acute pulmonary embolism (PE), covering multiple relevant aspects of patient counselling. It …
acute pulmonary embolism (PE), covering multiple relevant aspects of patient counselling. It …
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Cardiovascular Research, 2022 - academic.oup.com
Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome
coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels …
coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels …
2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of …
Writing Committee, MC Kontos, JA de Lemos… - Journal of the American …, 2022 - jacc.org
Copies: This document is available on the website of the American College of Cardiology
(www. acc. org). For copies of this document, please contact Elsevier Inc. Reprint …
(www. acc. org). For copies of this document, please contact Elsevier Inc. Reprint …
Bleeding avoidance strategies in percutaneous coronary intervention
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
F Gragnano, D Cao, L Pirondini, A Franzone… - Journal of the American …, 2023 - jacc.org
Background Aspirin is the only antiplatelet agent with a Class I recommendation for long-
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …